FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311751102> ?p ?o ?g. }

• W4311751102 abstract "Abstract Background Pseudomonas aeruginosa (Pa) is a common cause of nosocomial pneumonia; resistance among traditionally used empiric agents is observed frequently. To improve patient outcomes, a heightened focus has been placed on evaluating the adequacy of recommended dosing regimens, particularly of beta-lactams. The Phase 3 study ASPECT-NP demonstrated the efficacy and safety of 3 g of ceftolozane/tazobactam (C/T) infused every 8 h for 8 to 14 days for treatment of adults with Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia (HAP/VAP). We assessed the Probability of Target Attainment (PTA) of the C/T 3g dosage regimen in patients with HAP/VAP due to Pa, with an additional focus on carbapenem-resistant Pa, from Latin America. Methods Non duplicate Pa isolates from a respiratory source were collected as part of the SMART surveillance program from 36 sites in 10 Latin American countries during 2017-2020. MICs were determined by broth microdilution and interpreted by CLSI criteria. C and T concentration-time profiles were simulated in plasma and ELF following administration of the approved 3g (2g/1g) C/T dose (or equivalent dose adjusted based on renal function) administered by 1-hour infusion every 8 hours. PTA in plasma and ELF was calculated using the PK/PD target of 30% fT &gt; MIC for C. T does not contribute to the antipseudomonal activity of C and therefore was not considered. Results A total of 2,757 P. aeruginosa were collected, of which 1208 (43.8%) were carbapenem nonsusceptible. C/T susceptiblity was 87.7% against all Pa and 73.4% among carbapenem nonsusceptible strains. At C/T doses of 2g/1g (CrCL &gt; 50mL/min); 1g/0.5g (30mL/min≤ CrCL≤ 50mL/min), and 500mg/250mg (15mL/min≤ CrCL≤29mL/min), steady-state ceftolozane plasma and ELF PTA was 100% and &gt; 99%, respectively, for isolates with an MIC at the Pa susceptiblity breakpoint of 4 µg/mL. Ceftolozane plasma and ELF PTA remained above 90% up to an MIC of 16 µg/mL and 8 µg/mL, respectively. Conclusion The regulatory approved pneumonia dosage regimen of C/T 3g (administered over 1 hour) every 8 hours (or equivalent dose adjusted based on renal function) resulted in high plasma and ELF PTAs sufficient to cover the vast majority of circulating P. aeruginosa present in Latin America, including carbapenem resistant strains. Disclosures Aline Okuma, PharmD, MSD Brazil: Employee Thales Polis, MD, MSD Brazil: Employee Jacqueline Pavia, MD, MSD COLOMBIA: EMPLOYEE Gustavo Mizuno, PharmD, MSD Brazil: Employee Jacqueline Ferrari, MD, MSD Brazil: Employee Charles A. DeRyke, PharmD, Merck & Co., Inc. Merck Research Laboratories: Stocks/Bonds." @default.
• W4311751102 created "2022-12-28" @default.
• W4311751102 creator A5018204447 @default.
• W4311751102 creator A5029168488 @default.
• W4311751102 creator A5037643218 @default.
• W4311751102 creator A5046494936 @default.
• W4311751102 creator A5087616650 @default.
• W4311751102 creator A5090450543 @default.
• W4311751102 date "2022-12-01" @default.
• W4311751102 modified "2023-10-14" @default.
• W4311751102 title "624. Probability of Target Attainment of Ceftolozane/Tazobactam Among Adult Patients with Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Secondary to <i>Pseudomonas aeruginosa</i> in Latin America" @default.
• W4311751102 doi "https://doi.org/10.1093/ofid/ofac492.676" @default.
• W4311751102 hasPublicationYear "2022" @default.
• W4311751102 type Work @default.
• W4311751102 citedByCount "0" @default.
• W4311751102 crossrefType "journal-article" @default.
• W4311751102 hasAuthorship W4311751102A5018204447 @default.
• W4311751102 hasAuthorship W4311751102A5029168488 @default.
• W4311751102 hasAuthorship W4311751102A5037643218 @default.
• W4311751102 hasAuthorship W4311751102A5046494936 @default.
• W4311751102 hasAuthorship W4311751102A5087616650 @default.
• W4311751102 hasAuthorship W4311751102A5090450543 @default.
• W4311751102 hasBestOaLocation W43117511021 @default.
• W4311751102 hasConcept C126322002 @default.
• W4311751102 hasConcept C176947019 @default.
• W4311751102 hasConcept C2776685102 @default.
• W4311751102 hasConcept C2777288759 @default.
• W4311751102 hasConcept C2777637488 @default.
• W4311751102 hasConcept C2777858937 @default.
• W4311751102 hasConcept C2777914695 @default.
• W4311751102 hasConcept C2778193466 @default.
• W4311751102 hasConcept C2778266534 @default.
• W4311751102 hasConcept C2779631663 @default.
• W4311751102 hasConcept C2780950330 @default.
• W4311751102 hasConcept C2781413609 @default.
• W4311751102 hasConcept C501593827 @default.
• W4311751102 hasConcept C523546767 @default.
• W4311751102 hasConcept C54355233 @default.
• W4311751102 hasConcept C71924100 @default.
• W4311751102 hasConcept C86803240 @default.
• W4311751102 hasConcept C89423630 @default.
• W4311751102 hasConcept C94665300 @default.
• W4311751102 hasConceptScore W4311751102C126322002 @default.
• W4311751102 hasConceptScore W4311751102C176947019 @default.
• W4311751102 hasConceptScore W4311751102C2776685102 @default.
• W4311751102 hasConceptScore W4311751102C2777288759 @default.
• W4311751102 hasConceptScore W4311751102C2777637488 @default.
• W4311751102 hasConceptScore W4311751102C2777858937 @default.
• W4311751102 hasConceptScore W4311751102C2777914695 @default.
• W4311751102 hasConceptScore W4311751102C2778193466 @default.
• W4311751102 hasConceptScore W4311751102C2778266534 @default.
• W4311751102 hasConceptScore W4311751102C2779631663 @default.
• W4311751102 hasConceptScore W4311751102C2780950330 @default.
• W4311751102 hasConceptScore W4311751102C2781413609 @default.
• W4311751102 hasConceptScore W4311751102C501593827 @default.
• W4311751102 hasConceptScore W4311751102C523546767 @default.
• W4311751102 hasConceptScore W4311751102C54355233 @default.
• W4311751102 hasConceptScore W4311751102C71924100 @default.
• W4311751102 hasConceptScore W4311751102C86803240 @default.
• W4311751102 hasConceptScore W4311751102C89423630 @default.
• W4311751102 hasConceptScore W4311751102C94665300 @default.
• W4311751102 hasIssue "Supplement_2" @default.
• W4311751102 hasLocation W43117511021 @default.
• W4311751102 hasLocation W43117511022 @default.
• W4311751102 hasOpenAccess W4311751102 @default.
• W4311751102 hasPrimaryLocation W43117511021 @default.
• W4311751102 hasRelatedWork W1900993882 @default.
• W4311751102 hasRelatedWork W2335510796 @default.
• W4311751102 hasRelatedWork W2749854663 @default.
• W4311751102 hasRelatedWork W2915161553 @default.
• W4311751102 hasRelatedWork W2991382789 @default.
• W4311751102 hasRelatedWork W3097456628 @default.
• W4311751102 hasRelatedWork W3138687476 @default.
• W4311751102 hasRelatedWork W4235321041 @default.
• W4311751102 hasRelatedWork W4292689058 @default.
• W4311751102 hasRelatedWork W4311609616 @default.
• W4311751102 hasVolume "9" @default.
• W4311751102 isParatext "false" @default.
• W4311751102 isRetracted "false" @default.
• W4311751102 workType "article" @default.